Parataxis Korea, Inc. (KOSDAQ:288330)

South Korea flag South Korea · Delayed Price · Currency is KRW
851.00
-71.00 (-7.70%)
Last updated: Dec 10, 2025, 3:00 PM KST
-68.01%
Market Cap80.77B
Revenue (ttm)10.10M
Net Income (ttm)-17.01B
Shares Out87.60M
EPS (ttm)-286.77
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume851,671
Average Volume623,768
Open922.00
Previous Close922.00
Day's Range845.00 - 922.00
52-Week Range671.00 - 9,280.00
Beta2.00
RSI29.38
Earnings DateNov 10, 2025

About Parataxis Korea

Parataxis Korea, Inc., a clinical stage biotech company, engages in the development of therapeutics for the treatment of ulcerative colitis, fibrotic diseases, and cancers worldwide. Its products in pipeline includes BBT-401, a Pellino-1 inhibitor, which is in Phase I clinical trial for the treatment of ulcerative colitis; and BBT-877, an autotaxin inhibitor that is in Phase I clinical trial for the treatment of various fibrotic diseases, such as idiopathic pulmonary fibrosis. Bridge Biotherapeutics, Inc. has a research collaboration with Atomw... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2015
Employees 21
Stock Exchange KOSDAQ
Ticker Symbol 288330
Full Company Profile

Financial Performance

In 2024, Parataxis Korea's revenue was 2.18 million, a decrease of -97.82% compared to the previous year's 100.00 million. Losses were -19.76 billion, -53.32% less than in 2023.

Financial Statements

News

There is no news available yet.